Recent Updates
Recently added Catalysts
ENVB Positive Sentiment Score: 85/100

EB-003 Targets 5‑HT1B: Expanding Mental Health Promise [Meditech Today]

Wednesday, July 2, 2025 1 min read
Key Takeaway: Enveric Biosciences has revealed new data on EB-003, its lead neuroplastogen, which acts as an agonist at the serotonin 5-HT1B receptor. This discovery expands the therapeutic potential of EB-003 to include treatment for depression, Parkinson's disease, and migraines. The compound is positioned as a prescription-ready neuroplastogenic agent.
Price reaction · baseline $14.76 (2025-07-02T13:38:00.000Z) · hit during market hours · clean, no other ENVB news in the window
day 0 close · peak
+1.6%

Market Sentiment Analysis

POSITIVE FACTORS

  • EB-003 shows promise for treating multiple CNS conditions.
  • The compound is non-hallucinogenic, making it more acceptable for patients.
  • New data supports its candidacy as a prescription-ready agent.

Full Press Release Details

New data confirms Enveric’s lead neuroplastogen acts on a serotonin receptor tied to depression, Parkinson’s, and migraine. Enveric Biosciences has announced that EB-003, its oral, non-hallucinogenic neuroplastogen, also acts as an agonist at the serotonin 5‑HT1B receptor. The new receptor binding data broadens the compound’s therapeutic reach to central nervous system (CNS) conditions such as depression, Parkinson’s disease, and migraine, reinforcing its candidacy as a prescription-ready neuroplastogenic agent.
Full Article >>

Frequently Asked Questions

What is EB-003?

EB-003 is an oral, non-hallucinogenic neuroplastogen developed by Enveric Biosciences.

Which conditions does EB-003 target?

EB-003 targets central nervous system conditions like depression, Parkinson's disease, and migraines.

How does EB-003 work?

EB-003 acts as an agonist at the serotonin 5-HT1B receptor.

Is EB-003 ready for prescription use?

Yes, the new data reinforces EB-003's candidacy as a prescription-ready neuroplastogenic agent.

Tags: ENVB Viatris Investor Conferences Healthcare Enveric Biosciences EB-003 5-HT1B receptor CNS conditions depression
Last updated: Jul 2, 2025

Biotech snapshot

Cash runway
$5M liquidity · $1M/mo burn
~4 mo
High dilution risk